UCB to pocket $1.5bn from generics business sale
This article was originally published in Scrip
Executive Summary
Belgian pharma group UCB is to sell its US specialty generics business Kremers Urban Pharmaceuticals (KU) for $1.525bn in cash. Private equity companies Advent International and Avista Capital Partners are acquiring the business; Avista healthcare industry executive Brian Markison will become president and CEO of KU, succeeding George Stevenson, who will leave. Mr Markison was previously CEO of Fougera Pharmaceuticals, a dermatology company that was spun off from Nycomed in 2011 and sold to Sandoz in 2012.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.